PMID- 34164503
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 9
IP  - 10
DP  - 2021 May
TI  - Real-world hematological adverse events in Chinese patients with advanced ovarian 
      cancer treated with an individualized starting dose of niraparib.
PG  - 869
LID - 10.21037/atm-21-2252 [doi]
LID - 869
AB  - BACKGROUND: This work set out to examine the hematological adverse events (AEs) 
      of an individualized starting dose (ISD) of niraparib in Chinese patients with 
      ovarian cancer (OC). METHODS: The medical records of 43 patients with OC who were 
      treated with an ISD of niraparib at the Cancer Hospital of The University of 
      Chinese Academy of Sciences between February 2019 and January 2020 were 
      retrospectively reviewed. Treatment-emergent hematological AEs were analyzed. 
      RESULTS: Of the 43 patients with OC, 28 (65.1%) had hematological AEs of >/= grade 
      1, including thrombocytopenia (39.5%), leukopenia (37.2%), and anemia (34.9%). 
      Ten (23.3%) patients developed grade 3/4 hematological AEs, including 
      thrombocytopenia (11.6%), leukopenia (9.3%), and anemia (7.0%). Among the 
      individuals who developed AEs during treatment, 9 (32.1%) patients had their 
      treatment interrupted, with treatment being restarted in 8 (28.6%) cases, and 4 
      (14.3%) patients had the drug dose decreased. No deaths were reported. The median 
      times to the occurrence of any-grade leukopenia, anemia, and thrombocytopenia 
      were 30 (range, 7 to 162), 34 (range, 7 to 108), and 20 (range, 13 to 180) days, 
      respectively. Most AEs occurred within the first 3 months of treatment (93.8% 
      leukopenia, 80.0% anemia, and 76.5% thrombocytopenia). Treatments for AEs 
      included supplementation of recombinant human granulocyte colony-stimulating 
      factor (n=5, 17.9%), erythrocytes (n=2, 7.1%), and recombinant human 
      thrombopoietin (n=5, 17.9%). CONCLUSIONS: The incidence of adverse hematological 
      reactions to an ISD of niraparib in Chinese patients with advanced OC is 
      relatively lower in the real world than in the phase III clinical trials PRIMA 
      (also an ISD) and NOVA. These hematological AEs can be managed through dose 
      adjustment and symptomatic therapy.
CI  - 2021 Annals of Translational Medicine. All rights reserved.
FAU - Wang, Junjian
AU  - Wang J
AD  - Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
FAU - Zhu, Jianqing
AU  - Zhu J
AD  - Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8184470
OTO - NOTNLM
OT  - Ovarian cancer (OC)
OT  - adverse events (AEs)
OT  - niraparib
OT  - platinum-based chemotherapy
OT  - real-world study
COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-21-2252). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/06/25 06:00
MHDA- 2021/06/25 06:01
PMCR- 2021/05/01
CRDT- 2021/06/24 06:40
PHST- 2021/06/24 06:40 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/06/25 06:01 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - atm-09-10-869 [pii]
AID - 10.21037/atm-21-2252 [doi]
PST - ppublish
SO  - Ann Transl Med. 2021 May;9(10):869. doi: 10.21037/atm-21-2252.